Hope for Prevention of a Genetic Disease Before Birth

    Stanford medicine discovered a new technique to treat a rare genetic disorder called Fanconi anemia in babies before they are born. Fanconi anemia is a disease that causes a deficiency in DNA repair. So, when cells are dividing problems emerge in bone marrow not making blood and immune cells. This results in the children having lower energy levels, low platelet levels, headaches, greater risk of infections and cancer, and pale skin.

    This technique is done by a prenatal stem cell transplant. Pregnant moms donate healthy blood-forming stem cells which then are infused into her uterus through the umbilical cord. This treatment suggests that the features of the babies developing immune system can allow this transplant to settle the disorder before the baby is born. This technique is very new and Agnieszka Czechowicz, a Stanford Medicine pediatric hematologist who is responsible for this research, has only done this approach to the first research participants. Many questions still exist because the treatment has only started recently. However, a survey about what people think of the prenatal treatment concept showed that 100% of Fanconi amemia patients would undergo this prenatal diagnosis. 

Figure 1. Explanation of the Disease 

This article brings hope to everybody---but especially parents-to-be who are expecting their child to have this genetic disease. When the fetus has Fanconi anemia, they have a lower stem cell count so there is room for the mother's healthy blood-forming stem cells. This study was also tested in mice and was successful at other institutions as well. This research also believes that the children would never need subsequent therapies so they could live a typical life after birth. A major disease that could eventually affect the child later in life is cancer. If this prenatal transplant occurs, the child would not be at a high risk for cancer and have to deal with months of chemotherapy. Overall, these findings give people a reason to try to treat this disease before birth. Reading this article even affects me---someone who is not a parent to be. I think this technique should be used more to prevent long term effects. 

Source: https://med.stanford.edu/news/insights/2026/03/fanconi-anemia-prenatal-stem-cell-transplant-trial.html 

Link specifically about Fanconi anemia: https://my.clevelandclinic.org/health/diseases/14473-fanconi-anemia-fa 

Genetically modified organs

A new study in the Journal of Hepatology reports the first successful liver xenotransplant from a genetically engineered pig into a living human; a milestone that could reshape the future of organ transplantation. The 71-year-old patient, who was not eligible for a human liver transplant, received a graft from a modified pig engineered with 10 gene edits to improve compatibility. For more than a month, the pig liver carried out essential functions such as bile production and coagulation factor synthesis. Although the graft was removed on day 38 due to a complication known as xenotransplantation-associated thrombotic microangiopathy, the patient ultimately survived 171 days, demonstrating that a pig liver can operate inside a human body for an extended period.

                            

Researchers and global health experts view this case as an important early proof of concept at a time when thousands die each year waiting for donor organs. With organ shortages especially severe in countries like China, where liver failure cases far outnumber available transplants, this experimental success offers a glimpse of what future solutions may look like. Experts emphasize both the promise and the ongoing obstacles, but agree that the case marks a turning point. As editorialist Heiner Wedemeyer noted, genetically engineered pig organs may one day provide entirely new options for patients with liver failure, signaling the beginning of a new chapter in transplant medicine.